Maurizio Bonacini1. 1. Department of Transplantation, California Pacific Medical Center, San Francisco CA 94115, USA. bonacim@sutterhealth.org
Abstract
OBJECTIVE: To evaluate alcohol use in patients with HIV infection, assess ethnic and social associations, and describe outcomes. MATERIAL AND METHODS: design: cohort study. setting: Academic HIV-Liver Clinic. patients: 431 HIV-infected patients (371 men, 60 women); 249 patients with HIV/HCV coinfection, 115 HIV alone, and 67 with HIV/HBV. INTERVENTION: alcohol use was estimated at first interview and reported as the estimated average lifetime consumption in grams/day. outcome measures: laboratory values, liver fibrosis, decompensation and mortality. RESULTS: Twenty-two percent of patients in the entire cohort had high risk lifetime average alcohol consumption, defined as ≥ 50 mg/day. Fifty-six percent of patients had quit all alcohol when first evaluated, but follow-up showed that 26% continued high risk consumption. By univariate analysis high alcohol consumption was associated with Latino ethnicity, injection drug use (IDU) and hepatitis C (HCV) coinfection. Multivariable analysis showed only IDU to be independently associated with high alcohol consumption (RR = 4.1, p = 0.0005). There were no significant differences in laboratory values, including CD4 cell counts, except for a trend towards higher transaminases and liver fibrosis scores, between high and low alcohol users. All-cause mortality was statistically higher in the high (37%) vs. low (25%, p = 0.03) alcohol use group, and was associated with both IDU (RR = 2.2, p = 0.04) and the amount of alcohol consumed (RR = 1.1, p = 0.04). Liver decompensation and mortality were both higher in the high use group but of borderline significance. Using an ordinal grouping, we found a strong correlation (R =0.88) between alcohol consumption and the percentage of liver death over total deaths, with lowest mortality rates found in those use of 10 g/day or less. CONCLUSIONS: Unsafe use of alcohol is prevalent in HIV-infected patients and stoppage is not universal. There is a significant impact on all-cause mortality and a trend towards higher liver morbidity and mortality. IDU is significantly and independently associated with high ethanol intake. Practitioners should strongly recommend that HIV patients minimize alcohol use.
OBJECTIVE: To evaluate alcohol use in patients with HIV infection, assess ethnic and social associations, and describe outcomes. MATERIAL AND METHODS: design: cohort study. setting: Academic HIV-Liver Clinic. patients: 431 HIV-infectedpatients (371 men, 60 women); 249 patients with HIV/HCV coinfection, 115 HIV alone, and 67 with HIV/HBV. INTERVENTION: alcohol use was estimated at first interview and reported as the estimated average lifetime consumption in grams/day. outcome measures: laboratory values, liver fibrosis, decompensation and mortality. RESULTS: Twenty-two percent of patients in the entire cohort had high risk lifetime average alcohol consumption, defined as ≥ 50 mg/day. Fifty-six percent of patients had quit all alcohol when first evaluated, but follow-up showed that 26% continued high risk consumption. By univariate analysis high alcohol consumption was associated with Latino ethnicity, injection drug use (IDU) and hepatitis C (HCV) coinfection. Multivariable analysis showed only IDU to be independently associated with high alcohol consumption (RR = 4.1, p = 0.0005). There were no significant differences in laboratory values, including CD4 cell counts, except for a trend towards higher transaminases and liver fibrosis scores, between high and low alcohol users. All-cause mortality was statistically higher in the high (37%) vs. low (25%, p = 0.03) alcohol use group, and was associated with both IDU (RR = 2.2, p = 0.04) and the amount of alcohol consumed (RR = 1.1, p = 0.04). Liver decompensation and mortality were both higher in the high use group but of borderline significance. Using an ordinal grouping, we found a strong correlation (R =0.88) between alcohol consumption and the percentage of liver death over total deaths, with lowest mortality rates found in those use of 10 g/day or less. CONCLUSIONS: Unsafe use of alcohol is prevalent in HIV-infectedpatients and stoppage is not universal. There is a significant impact on all-cause mortality and a trend towards higher liver morbidity and mortality. IDU is significantly and independently associated with high ethanol intake. Practitioners should strongly recommend that HIVpatients minimize alcohol use.
Authors: Michael J Silverberg; Tory Levine-Hall; Nicole Hood; Alexandra N Anderson; Stacey E Alexeeff; Jennifer O Lam; Sally B Slome; Jason A Flamm; Charles Bradley Hare; Thekla Ross; Amy C Justice; Jonathan A C Sterne; Andrew E Williams; Kendall J Bryant; Constance M Weisner; Michael A Horberg; Stacy A Sterling; Derek D Satre Journal: Alcohol Clin Exp Res Date: 2020-11-10 Impact factor: 3.455
Authors: Elinore F McCance-Katz; Valerie A Gruber; George Beatty; Paula Lum; Qing Ma; Robin DiFrancesco; Jill Hochreiter; Paul K Wallace; Morris D Faiman; Gene D Morse Journal: Am J Addict Date: 2013-10-11
Authors: Jennifer C Elliott; Efrat Aharonovich; Ann O'Leary; Barbara Johnston; Deborah S Hasin Journal: Alcohol Clin Exp Res Date: 2014-12 Impact factor: 3.455
Authors: Brian T Montague; Christopher W Kahler; Suzanne M Colby; R Kathryn McHugh; Daniel Squires; Brianne Fitzgerald; Don Operario; Donna Gallagher; Peter M Monti; Kenneth H Mayer Journal: Addict Disord Their Treat Date: 2015-03
Authors: Adolf Pfefferbaum; Margaret J Rosenbloom; Stephanie A Sassoon; Carol A Kemper; Stanley Deresinski; Torsten Rohlfing; Edith V Sullivan Journal: Biol Psychiatry Date: 2012-03-27 Impact factor: 13.382